CLNN

Clene Inc.

Add to Watchlist

Advanced Chart

5.320

-0.09(-1.664%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.650

Open

5.420

VWAP

5.33

Vol

33.73K

Mkt Cap

53.15M

Low

5.270

Amount

179.87K

EV/EBITDA(TTM)

Total Shares

128.43M

56.71M

EV/OCF(TTM)

P/S(TTM)

154.95

Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. It specializes in the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. CNM-Au8, the lead asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. CNM-Au8’s mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for the treatment of infectious diseases and to support wound healing.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

63.00K

-22.22%

-0.645

+616.67%

58.00K

-36.26%

-0.480

-71.26%

55.14K

-36.62%

-0.558

-54.24%

Estimates Revision

The market is revising Downward the revenue expectations for Clene Inc. (CLNN) for FY2025, with the revenue forecasts being adjusted by -2.14% over the past three months. During the same period, the stock price has changed by 8.57%.

Revenue Estimates for FY2025

Revise Downward

-2.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+17.21%

In Past 3 Month

Stock Price

Go Up

+8.57%

In Past 3 Month

5 Analyst Rating

401.88% Upside

Wall Street analysts forecast CLNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLNN is 26.70 USD with a low forecast of 4.50 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

401.88% Upside

Current: 5.320

Low

4.50

Averages

26.70

High

48.00

401.88% Upside

Current: 5.320

Low

4.50

Averages

26.70

High

48.00

Canaccord

Buy

downgrade

$83 -> $48

2025-08-18

Reason

Canaccord

Price Target

$83 -> $48

2025-08-18

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Clene to $48 from $83 and keeps a Buy rating on the shares. The firm updated its model following Q2 results but admits clarity from the FDA on its ability to file for accelerated approval or not for its ALS and Ms drugs are the key. They now include contributions from ALS and MS at probabilities of approval of 33% and 20%, respectively in their model.

Jones Trading

Justin Walsh

Strong Buy

Initiates

$30

2025-04-23

Reason

Jones Trading

Justin Walsh

Price Target

$30

2025-04-23

Initiates

Strong Buy

Reason

JonesResearch analyst Justin Walsh initiated coverage of Clene with a Buy rating and $30 price target. Clene is a clinical-stage pharmaceutical company developing nanothechnology therapeutics for the treatment of central nervous system disorders, the analyst tells investors in a research note. The firm says the company's clinical setbacks in amyotrophic lateral sclerosis "are not the end of the story." The market has written off potential accelerated approval prematurely, contends JonesResearch.

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$31

2025-04-08

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$31

2025-04-08

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$23

2025-04-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

$23

2025-04-08

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

$31

2025-03-25

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$31

2025-03-25

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$23

2025-03-24

Reason

D. Boral Capital

Jason Kolbert

Price Target

$23

2025-03-24

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Clene Inc. (CLNN.O) is -2.35, compared to its 5-year average forward P/E of -6.30. For a more detailed relative valuation and DCF analysis to assess Clene Inc. 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.30

Current PE

-2.35

Overvalued PE

1.68

Undervalued PE

-14.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.43

Current EV/EBITDA

-2.46

Overvalued EV/EBITDA

-0.26

Undervalued EV/EBITDA

-2.60

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

441.24

Current PS

222.29

Overvalued PS

926.50

Undervalued PS

-44.02